GlaxoSmithKline | GSK - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Alcon AG USD 297M 16M 2026-03
Almirall EUR 71.55M 41.32M 2026-06
Amgen USD 4.61B 777M 2026-06
argenx SE USD 493M 99M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD -243.8M 758.1M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Fresenius EUR 719M 118M 2026-06
Fresenius Medical Care EUR 268M 395M 2026-03
Genmab DKK 407M 182M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
GRIFOLS EUR 329M 80M 2026-06
Hikma Pharmaceutical USD 348M 161M 2025-12
Lakefront Biotherapeutics EUR -63.7M 844.26M 2026-03
Lonza CHF 673M 243M 2025-06
Merck EUR 1.05B 572M 2026-03
Merck USD 840M 2.72B 2026-06
Novartis USD 4.75B 515M 2026-06
Novo Nordisk DKK 33.76B 25.86B 2026-06
Orion EUR 176.6M 61.8M 2026-06
Pfizer USD 667M 4.32B 2026-06
Philips EUR 610M 308M 2026-06
Recordati EUR 203.76M 27.35M 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 2.38B 449M 2026-06
Smith & Nephew USD 505M 65M 2026-06
UCB EUR 1.29B 571M 2025-12